zur Navigation zum Inhalt

Kongresse 2012

What’s new in Hodgkin’s lymphoma: ASH 2012 and more

10/2013 Modern treatment strategies have resulted in an excellent overall survival in the majority of patients with Hodgkin’s lymphoma. PET-stratification is used to guide treatment in patients with limited disease in clinical trials, but recent results indicate that combined treatment with chemotherapy and radiotherapy is still the standard of care. [...]

Aggressive lymphoma at ASH 2012: new standards and new perspectives

10/2013 Recent clinical data presented at the annual meeting of the American Society of Hematology underline the importance of incorporating cytarabine in the induction treatment of younger patients with mantle cell lymphoma, while other trials confirmed the importance of immuno-chemotherapy with rituximab and bendamustine, especially in elderly patients. [...]

Georgia on my mind: multiple myeloma highlights at ASH 2012

10/2013 Clonal evolutionary models of myeloma progression were the main focus with respect to basic science highlights at ASH 2012. The well-documented evidence for the existence of a “Darwinian-branching” evolution pattern has major clinical implications for the development of new treatment strategies and disease monitoring. [...]

ASH 2012: “Helping hematologists conquer blood diseases worldwide”

10/2013 The 54th annual meeting of the American Society of Hematology (ASH) held in Atlanta, Georgia, 8th–11th December 2012, was attended by 21,000 participants from over 110 countries. Selecting the most relevant data out of a wealth of > 5,000 abstracts and > 3,000 presentations represents a major challenge. [...]

Philadelphia-negative myeloproliferative neoplasms at the 2012 ASH meeting: a personal summary

10/2013 This short and personal overview summarizes new data in the field of myeloproliferative neoplasms from the 2012 American Society of Hematology meeting. In Polycythemia vera (PV) an hematocrit strictly kept below 45 % was shown to be associated with a lower cardiovascular event rate. [...]

ASH 2012: allogeneic stem cell transplantation

10/2013 Hematopoietic stem cell transplantation (HSCT) is a developing treatment modality, continuously being adapted to disease-specific requirements, and, even more successfully, to the tolerability in a growing target population. [...]

Medizin heute

Aktuelle Printausgaben